OBJECTIVES: Effects of multiple trauma are complex and extend beyond core PTSD symptoms. However, few psychological instruments for trauma assessment address this issue of symptom complexity. The Trauma Symptom Checklist-40 (TSC-40) is a self-report scale that assesses wide range of symptoms associated with childhood or adult traumatic experience. The purpose of the present study was to evaluate the validity of the Korean Version of the TSC-40 in a sample of psychiatric outpatients. METHODS: Data of 367 treatment-seeking patients with DSM-IV diagnoses were obtained from an outpatient department of psychiatric unit at a university hospital. The diagnoses were anxiety disorder, posttraumatic stress disorder, depressive disorder, adjustment disorder and others. Included in the psychometric data were the TSC-40, the Life events checklist, the Impact of Event Scale-Revised, the Zung's Self-report Depression Scale, and the Zung's Self-report Anxiety Scale. Cronbach's α for internal consistency were calculated. Convergent and concurrent validity was approached with correlation between the TSC-40 and other scales (PTSD, anxiety and depression). RESULTS: Exploratory factor analysis of the Korean Version of TSC-40 extracted seven-factor structure accounted for 59.55% of total variance that was contextually similar to a six-factor structure and five-factor structure of the original English version. The Korean Version of TSC-40 demonstrated a high level of internal consistency. (Cronbach's α=0.94) and good concurrent and convergent validity with another PTSD scale and anxiety and depression scales. CONCLUSIONS: Excellent construct validity of The Korean Version of TSC-40 was proved in this study. And subtle difference in the factor structure may reflect the cultural issues and the sample characteristics such as heterogeneous clinical population (including non-trauma related disorders) and outpatient status. Overall, this study TSCdemonstrated that the Korean version of TSC-40 is psychometrically sound and can be used for Korean clinical population.
Adjustment Disorders ; Adult ; Anxiety ; Anxiety Disorders ; Checklist ; Depression ; Depressive Disorder ; Diagnosis ; Diagnostic and Statistical Manual of Mental Disorders ; Humans ; Multiple Trauma ; Outpatients ; Psychometrics ; Stress Disorders, Post-Traumatic ; Weights and Measures

Anti-Mullerian hormone (AMH), also called Mullerian-inhibiting substance, is a member of the transforming growth factor (TGF)-beta superfamily. It is well known that AMH is expressed by Sertoli cells in fetal testis, and that it induces Mullerian duct degeneration during male fetal development. However, in females AMH is produced by granulosa cells of the ovarian follicles. Recently, numerous studies have demonstrated that AMH could be a useful marker of ovarian function. Serum AMH levels decrease progressively with age, become undetectable after menopause, and show high cycle-to-cycle reproducibility. It has been shown that AMH level is correlated with various outcomes of controlled ovarian hyperstimulation (COH). Many studies showed that AMH can discriminate very effectively poor responders, cycle cancellation, and ovarian hyperstimulation syndrome after COH. AMH also has a functional role in folliculogenesis and could be a qualitative marker of ovarian follicular states. In addition, AMH has been associated with various clinical statuses such as polycystic ovarian syndrome, endometriosis, obesity, granulosa cell tumor, and premature ovarian failure. AMH is an effective and promising biomarker of various conditions in female reproduction. In this article, current research results on role of AMH as a marker of ovarian function and dysfunction are discussed.
Anti-Mullerian Hormone ; Endometriosis ; Female ; Fetal Development ; Granulosa Cell Tumor ; Granulosa Cells ; Humans ; Male ; Menopause ; Obesity ; Ovarian Follicle ; Ovarian Hyperstimulation Syndrome ; Polycystic Ovary Syndrome ; Primary Ovarian Insufficiency ; Reproduction ; Sertoli Cells ; Testis ; Transforming Growth Factors

Cancer is not rare in women in reproductive ages, and there has been a remarkable improvement in the survival rates due to progress in cancer treatment. Moreover, women have been delaying the initiation of childbearing to later in life. Thus the preservation of fertility in female cancer survivors has become an important health issue. Because of the variations in the type of cancer, type and dose of chemotherapy, the time available before onset of treatment, the patient's age, and the status of partners, each case should be individualized and requires a different strategy in fertility preservation. When a partner or donor sperm is available, embryo cryopreservation is now an established and acceptable technique for fertility preservation, providing a delay in the initiation of chemotherapy or radiotherapy. Oocyte cryopreservation is available for women without partners, but there is a limited experience with this technique and pregnancy rate is still low. In spite of the recent reports of successful birth after autotransplantation of cryopreserved-thawed human ovarian tissue, clinical experience is also limited and this technique remains still experimental. Further researches for establishing optimal cryopreservation and thawing protocols and increasing post-thawing survival, pregnancy, and delivery rates are necessary. In this article, the mechanisms of reproductive failure after cancer therapy and the strategies for fertility preservation in cancer survivors are discussed.
Cryopreservation ; Embryonic Structures ; Female ; Fertility ; Fertility Preservation ; Humans ; Oocytes ; Parturition ; Pregnancy ; Pregnancy Rate ; Spermatozoa ; Survival Rate ; Survivors ; Tissue Donors

Although many models have been proposed to accurately predict the response of drugs in cell lines recent years, understanding the genome related to drug response is also the key for completing oncology precision medicine. In this paper, based on the cancer cell line gene expression and the drug response data, we established a reliable and accurate drug response prediction model and found predictor genes for some drugs of interest. To this end, we first performed pre-selection of genes based on the Pearson correlation coefficient and then used ElasticNet regression model for drug response prediction and fine gene selection. To find more reliable set of predictor genes, we performed regression twice for each drug, one with IC50 and the other with area under the curve (AUC) (or activity area). For the 12 drugs we tested, the predictive performance in terms of Pearson correlation coefficient exceeded 0.6 and the highest one was 17-AAG for which Pearson correlation coefficient was 0.811 for IC50 and 0.81 for AUC. We identify common predictor genes for IC50 and AUC, with which the performance was similar to those with genes separately found for IC50 and AUC, but with much smaller number of predictor genes. By using only common predictor genes, the highest performance was AZD6244 (0.8016 for IC50, 0.7945 for AUC) with 321 predictor genes.

Although many models have been proposed to accurately predict the response of drugs in cell lines recent years, understanding the genome related to drug response is also the key for completing oncology precision medicine. In this paper, based on the cancer cell line gene expression and the drug response data, we established a reliable and accurate drug response prediction model and found predictor genes for some drugs of interest. To this end, we first performed pre-selection of genes based on the Pearson correlation coefficient and then used ElasticNet regression model for drug response prediction and fine gene selection. To find more reliable set of predictor genes, we performed regression twice for each drug, one with IC50 and the other with area under the curve (AUC) (or activity area). For the 12 drugs we tested, the predictive performance in terms of Pearson correlation coefficient exceeded 0.6 and the highest one was 17-AAG for which Pearson correlation coefficient was 0.811 for IC50 and 0.81 for AUC. We identify common predictor genes for IC50 and AUC, with which the performance was similar to those with genes separately found for IC50 and AUC, but with much smaller number of predictor genes. By using only common predictor genes, the highest performance was AZD6244 (0.8016 for IC50, 0.7945 for AUC) with 321 predictor genes.

PURPOSE: To investigate the direct relationship between the follicular fluid (FF) level of soluble human leukocyte antigen G (HLA-G) and fertilizability of the corresponding oocyte as well as the morphological quality of the corresponding embryo. MATERIALS AND METHODS: Sixty-three patients were stimulated with recombinant FSH combined with gonadotropin-releasing hormone (GnRH) agonist long (n=5) or antagonist protocol (n=58) for standard in vitro fertilization (IVF). At the time oocyte retrieval, follicular fluid was obtained from single dominant follicle in 63 patients, and the level of soluble HLA-G was measured by sandwich enzyme-liked immunosorbent assay (ELISA). Normal fertilization and individual embryo quality were evaluated, and were graded to four categories by morphological criteria (the embryo with symmetrical blastomeres and no fragmentation were assigned as grade A). Good-quality embryo was defined as those with grade A or B. RESULTS: Soluble HLA-G was not detected in 15 FF samples. In the group with positive FF soluble HLA-G (sHLA-G) (n=48), high levels of sHLA-G (>117.758 U/mL) could predict the failure of fertilization with statistical significance {area under the curve (AUC) 0.676, 95% confidence interval (CI) 0.525-0.804}. However, the FF sHLA-G level was not related with the formation of good-quality embryo. CONCLUSION: High level of FF sHLA-G could predict the fertilization failure of the corresponding oocyte, but was not related with the formation of good-quality embryo.
Adult ; Enzyme-Linked Immunosorbent Assay ; Female ; Follicular Fluid/*metabolism ; HLA-G Antigens/*metabolism ; Humans ; Oocytes/*cytology/physiology ; Ovarian Follicle/*cytology/physiology

The aim of this study was to evaluate the clinical efficacy of body mass index (BMI) as a predictor of in vitro fertilization and embryo transfer (IVF-ET) outcomes. Two hundred twenty-three IVF-ET cycles in 164 patients under 37 yr using GnRH agonist long protocols were included in this retrospective study. All of the selected cases were divided into two groups by a cutoff of 24 kg/m2 and these two groups were compared in regard to the outcomes of IVF-ET. There were no significant differences between group 1 (BMI <24 kg/m2) and group 2 (BMI > or = 24 kg/m2) in age, basal serum FSH level, estradiol (E2) level and endometrial thickness on hCG day, number of retrieved oocytes and transferred embryos. However, higher doses of gonadotropins were used in group 2 (30.8+/-12.7 ampoules vs. 35.4+/-15.3 ampoules, p=0.051). The clinical pregnancy rate was significantly lower in group 2 (25.9% vs. 10.5%, p=0.041) and implantation rate tended to be lower in group 2 (12.7% vs. 6.8%, p=0.085). BMI > or = 24 kg/m2 can be a candidate prognosticator of IVF-ET outcomes.
Treatment Outcome ; Prognosis ; Pregnancy ; Obesity/complications/pathology ; Infertility, Female/complications/pathology/therapy ; Humans ; *Fertilization in Vitro ; Female ; *Embryo Transfer ; Embryo Implantation ; *Body Mass Index ; Adult

OBJECTIVE: To evaluate the clinical efficacy of body mass index (BMI) as a predictor of in vitro fertilization and embryo transfer (IVF-ET) outcomes. METHODS: Two hundred twenty-three IVF-ET cycles in 164 patients under 37 years using GnRH agonist long protocol were included in this retrospective study. All of the selected cases were divided into two groups by BMI of 24 kg/m2 and these two groups were compared in regard to the outcomes of IVF-ET. RESULTS: There were no significant differences between Group 1 (BMI<24 kg/m2) and Group 2 (BMI> or =24 kg/m2) in age, basal serum FSH level, estradiol (E2) level and endometrial thickness on hCG day, number of retrieved oocytes and transferred embryos. However, more gonadotropins were used in Group 2 with borderline significance (30.8+/-12.7 ampules vs. 35.4+/-15.3 ampules, p=0.051). The clinical pregnancy rate was significantly lower in Group 2 (25.9% vs. 10.5%, p=0.041) and implantation rate tended to be lower in Group 2 with borderline significance (12.7% vs. 6.8%, p=0.085). CONCLUSION: BMI> or =24 kg/m2 may have a detrimental effect on the IVF-ET outcomes in Korean infertile women, and BMI may be a candidate predictor for IVF outcomes.
Body Mass Index* ; Embryo Transfer* ; Embryonic Structures* ; Estradiol ; Female ; Fertilization in Vitro* ; Gonadotropin-Releasing Hormone ; Gonadotropins ; Humans ; Oocytes ; Pregnancy ; Pregnancy Rate ; Retrospective Studies

OBJECTIVE: To explore the association of estrogen receptor (ER) alpha gene PvuII and XbaI polymorphisms and ultrasonographic findings of uterine endometrium. METHODS: Forty-five postmenopausal women undergoing hormone replacement therapy (HRT) were included in this study. Women were evaluated for PvuII and XbaI polymorphisms for ER alpha gene after extracting DNA from peripheral blood. The thickness and appearance of uterine endometrium was measured by transvaginal ultrasonography. The association of estrogen receptor gene PvuII and XbaI polymorphisms and ultrasonographic endometrial findings were analyzed. RESULTS: No statistically significant difference was found in endometrial thickness (pp 3.6 +/- 1.5 mm, Pp 4.2 +/- 1.6 mm, PP 3.5 +/- 1.3 mm) or endometrial appearance among the three different groups by PvuII polymorphism. No significant difference was also observed in endometrial thickness (xx 3.6 +/- 1.5 mm, Xx 4.2 +/- 1.4 mm) or endometrial appearance between the two groups of different XbaI genotypes. CONCLUSION: These results suggest that neither PvuII nor XbaI polymorphism of the estrogen receptor alpha gene may be associated with the ultrasonographic findings of uterine endometrium in postmenopausal women undergoing HRT. Further studies with a larger scale are necessary to confirm these data.
DNA ; Endometrium* ; Estrogen Receptor alpha ; Estrogens* ; Female ; Genotype ; Hormone Replacement Therapy* ; Humans ; Ultrasonography